▼2019年

1.Sumi T, Ikeda T, Kure K, Yamada Y, Nakata H, Mori Y. Bronchomediastinal Fistula During Durvalumab Therapy After Chemoradiotherapy in Stage III NSCLC. J Thorac Oncol. 2019 Oct；14(10):1860-1861.

2.Sumi T, Ikeda T, Nakata H. Asymptomatic congenital tracheal stenosis. Respirol Case Rep. 2019 Aug 1；7(7):e00472.

▼2020年

1.Sumi T, Nakata H, Mori Y, Takahashi H. Anaplastic thyroid carcinoma with endotracheal metastasis diagnosed using transesophageal ultrasound-guided bronchoscopic aspiration. Jpn J Clin Oncol. 2020 Jan 24；50(1):94-95.

2.Sumi T, Nakata H, Mori Y, Takahashi H. Tegafur/gimeracil/oteracil-induced Eosinophilic Pneumonia. Respirol Case Rep. 2020； 8 (4), e00551.

3.Sumi T, Ikeda T, Sawai T, Shijubou N, Kure K, Yamada Y, Nakata H, Mori Y, Takahashi H. Comparison of Ultrathin Bronchoscopy to Conventional Bronchoscopy in the Bronchoscopic Diagnosis of Peripheral Lung Lesions, without Virtual Bronchial Navigation. Respir Investig. 2020； 58: 276-380.

4.Sumi T, Sawai T, Shijubou N, Yamada Y, Nakata H, Mori Y, Takahashi H.　 Lung adenocarcinoma observed within a peripheral cavitary lesion using an ultrathin bronchoscope. Jpn J Clin Oncol. 2020； 50: 1479-1480.

5.四十坊　直貴, 角　俊行, 澤井　健之, 山田　裕一, 計良　淑子, 中田　尚志, 森　裕二, 高橋　弘毅．ペムブロリズマブ長期奏功後に肺胞出血を呈した肺扁平上皮癌の1例．肺癌.2020；60:353-357

6.Sumi T, Uehara H, Masaoka T, Tada M, Keira Y, Kamada K, Shijubou N, Yamada Y, Nakata H, Mori Y, Chiba H. Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: a case report. Thoracic cancer. 2020； 11: 3396-3400.

▼2021年

1.Sumi T, Kamada K, Sawai T, Shijubou N, Yamada Y, Nakata H, Mori Y, Chiba H. Sedation with fentanyl and midazolam without oropharyngeal anesthesia compared with sedation with pethidine and midazolam with oropharyngeal anesthesia in ultrathin bronchoscopy for peripheral lung lesions. Respir Investig. 2021 Mar；59(2):228-234.

2.四十坊　直貴, 角　俊行, 鎌田　弘毅, 山田　裕一,中田　尚志, 森　裕二, 千葉　弘文．殺細胞性抗がん剤と免疫チェックポイント阻害薬併用療法の長期奏効後に免疫関連神経障害としてのギランバレー症候群を発症した一例．肺癌．2021； 61: 24–29.

3.Shijubou N, Sumi T, Kamada K, Sawai T, Yamada Y, Nakata H, Mori Y, Chiba H. Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma. Thorac Cancer. 2021 Mar；12(6):989-992.

4.Sumi T, Uehara H, Tada M, Keira Y, Kamada K, Shijubou N, Yamada Y, Nakata H, Mori Y, Chiba H. Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis-associated interstitial lung disease. Respirol Case Rep. 2021 Jan 27；9(3):e00716.

5.Shijubou N, Sumi T, Kamada K, Yamada Y, Nakata H, Chiba H. Diffuse alveolar haemorrhage due to pheochromocytoma crisis. Respirol Case Rep. 2021 Feb 25；9(4):e00722.

6.Sumi T, Nakata H, Mori Y, Chiba H. Pseudomesotheliomatous carcinoma of lung adenocarcinoma diagnosed using transesophageal ultrasound-guided bronchoscopic aspiration. Thorac Cancer. 2021 May；12(9):1465-1466.

7.Sumi T, Nakata H, Chiba H. Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment. Lung Cancer. 2021 May；155:196-198.

8.Sumi T, Kamada K, Shijubou N, Yamada Y, Nakata H, Mori Y, Chiba H. Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review. Respirol Case Rep. 2021 May 4；9(6):e00759.

9.Shijubou N, Sumi T, Kamada K, Sawai T, Yamada Y, Ikeda T, Nakata H, Mori Y, Chiba H. Fulminant amebic colitis in a patient with concomitant cytomegalovirus infection after systemic steroid therapy: A case report. World J Clin Cases. 2021 May 26；9(15):3726-3732.

10.Naraoka T, Sumi T, Keira Y, Nakata H, Chiba H. Epirubicin and cyclophosphamide-induced acute fibrinous and organizing pneumonia. Am J Respir Crit Care Med. 2021 Oct 15；204(8):e92-e93.

11.Sumi T, Shijubou N, Sawai T, Kamada K, Yamada Y, Nakata H, Mori Y, Chiba H. Transbronchial Needle Aspiration with Endobronchial Ultrasonography and Ultrathin Bronchoscopy for Peripheral Pulmonary Lesions.   Respir Investig. 2021 Nov；59(6):766-771

12.Sumi T, Nakata H, Chiba H. Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer. Thorac Cancer. 2021 Jul；12(13):2050-2052.

13.Shijubou N, Sumi T, Keira Y, Shiraishi H, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H, Chiba H. Pseudocirrhosis due to liver metastasis from lung adenocarcinoma. Thorac Cancer. 2021 Sep；12(17):2407-2410.

14.Sumi T, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H, et al. Delayed local reaction at a previous injection site reaction with dupilumab. Respirology Case Reports. 2021；9:e0852.

15.Sumi T, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H, Chiba H. Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech). Thorac Cancer. 2021 Oct 6. doi: 10.1111/1759-7714.14179. Epub ahead of print.

16.Sumi T, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H, Chiba H. Successful management of severe bronchial asthma exacerbated by anti-PD-L1 treatment: a report of two cases. Respirology Case Reports. Respirol Case Rep. 2021；9:e00868.

17.Matsuura K, Tada M, Sumi T, Osuda K, Nakata H, Chiba H. Unexpected haemorrhage from lateral thoracic artery following the removal of a pleural drainage tube. Respirology Case Reports. 2021；9:e0882.

18.Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, Isobe H； Hokkaido Lung Cancer Clinical Study Group Trial. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). Sci Rep. 2021 Nov 30；11(1):23140.

▼2022年

1.鎌田弘毅，四十坊直貴，角俊行，山田裕一，中田尚志，千葉弘文．免疫チェックポイント阻害薬と化学療法併用後に腎障害を発症しステロイド投与と一時的血液透析併用で改善し得た一例．肺癌．2022；62：221─226．

2.Shijubou N, Sumi T, Yamada Y, Nakata H, Mori Y, Chiba H. Immunological and nutritional predictive factors in patients receiving pembrolizumab first-line treatment for non-small cell lung cancer. J Cancer Res Clin Oncol. 2022;148(8):1893-1901.

3.Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S. Current status of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression. Cancer Sci. 2022;113(6):2109-2117.

4.Takeda K, Sumi T, Nagahisa Y, Matsuura K, Sekikawa M, Watanabe H, Yamada Y, Chiba H. Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report. Allergy Asthma Clin Immunol. 2022;18(1):35.

5.武田和也，角俊行，長久裕太，松浦啓吾，関川元基，渡辺 裕樹，山田裕一，中田尚志．生物学的製剤使用中の重症気管支喘息において増悪の原因としてニューモシスチス肺炎が考えられた1例．道南医ジ；5 (1)：7─10，2022．

6.Michimata H, Sumi T, Keira Y, et al. Intravascular large B cell lymphoma with hot lung sign diagnosed by transbronchial lung cryobiopsy. QJM. 2022;115(10):677–678.

7.関川元基，角俊行，江濵由松，川村亮太，武田和也，長久裕太，松浦啓吾，渡辺裕樹，山田裕一，千葉弘文．Carboplatin＋Paclitaxel＋Nivolumab＋Ipilimumab療法のinfusion related reactionによる心停止後に救命し得た非小細胞肺癌の一例．肺癌．2022；62：1021–1025．

8.長久裕太，角俊行，関川元基，武田和也，松浦啓吾，渡辺裕樹，山田裕一，計良淑子，千葉弘文．アレクチニブによる間質性肺疾患後にブリグチニブを使用したALK融合遺伝子陽性肺腺癌の2症例．肺癌．2022；62：1038–1043．

9.Sumi T, Michimata H, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Chiba H. Tumor-Associated Raynaud's Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors. J Thorac Oncol. 2022 Oct;17(10):1233-1234. doi: 10.1016/j.jtho.2022.07.004. PMID: 36192079.

10.Sumi T, Koshino Y, Michimata H, Nagayama D, Watanabe H, Yamada Y, Chiba H. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report. Transl Lung Cancer Res. 2022 Sep;11(9):1973-1976. doi: 10.21037/tlcr-22-388. PMID: 36248324; PMCID: PMC9554683.

11.Nagayama D, Sumi T, Keira Y, Tanaka Y, Michimata H, Koshino Y, Watanabe H, Yamada Y, Chiba H. Diffuse large B-cell lymphoma with cardiac invasion diagnosed using transesophageal ultrasound-guided bronchoscopic aspiration. Respirol Case Rep. 2022 Aug 15;10(9):e01022.

12.Michimata H, Sumi T, Keira Y, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Tanaka Y, Chiba H. Hemothorax as a complication of transbronchial lung cryobiopsy. Respirol Case Rep. 2022 Sep 5;10(10):e01034. doi: 10.1002/rcr2.1034. PMID: 36090021; PMCID: PMC9443670.

13.Watanabe H, Sumi T, Keira Y. Charcoal maker's pneumoconiosis. Respirol Case Rep. 2022;10(10):e01040.

14.Sumi T, Sekikawa M, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Watanabe H, Yamada Y, Tanaka Y, Chiba H. Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer. Invest New Drugs. 2022;40(6):1315-1321.

15.Sumi T, Koshino Y, Sekikawa M, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Watanabe H, Michimata H, Nagayama D, Tanaka Y, Yamada Y, Chiba H. Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer. Invest New Drugs. 2022;40(6):1298-1305.

▼2023年

1.Takahashi T, Sumi T, Michimata H, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Chiba H. Fatal diffuse alveolar hemorrhage caused by acute COVID-19 infection in an unvaccinated patient. QJM: An International Journal of Medicine, 2023;116:521–522.

2.Sumi T, Takeda K, Michimata H, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Kodama K, Nishikiori H, Chiba H. Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma: A Case Report. Intern Med. 2023;62:3381–3385.

3.Sumi T, Takahashi T, Michimata H, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Kodama K, Nishikiori H, Chiba H. Exacerbation of hypersensitivity pneumonitis induced by COVID-19. QJM. 2023 Mar 27;116(3):235-236. doi: 10.1093/qjmed/hcad021.

4.Michimata H, Sumi T, Nagayama D, et al. Severe heart failure due to peripartum cardiomyopathy. Respirol Case Rep. 2023;11(5):e01137.

5.Sumi T, Kodama K, Nishikiori H, Tanaka Y, Chiba H. Coronavirus Disease 2019 Vaccine-Induced Flare-Up of Severe Bronchial Asthma Previously Controlled With Dupilumab: A Case Report. Cureus. 2023 Apr 25;15(4):e38122.

6.Sumi T, Takahashi T, Terai K, Chiba H. Waldenström macroglobulinemia diagnosed by bronchoalveolar lavage. Jpn J Clin Oncol. 2023;53:738-740.

7.Sumi T, Terai K, Chiba H. Spontaneously expectorated EGFR-mutant non-small-cell lung cancer. Jpn J Clin Oncol. 2023;53;1094–1095.

8.Sumi T, Nagayama D, Michimata H, Koshino Y, Watanabe H, Yamada Y, Terai K, Chiba H. Diagnosis of lymphangitis carcinomatosa using cryobiopsy after surgical treatment for lung adenocarcinoma. Respir Endosc. 2023;1(2):65-68.

9.Sumi T, Michimata H, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H. Usefulness of transesophageal ultrasound-guided bronchoscopic aspiration for neoplastic lesions inside and outside of the lungs adjacent to the esophagus. Respir Endosc. 2023;1(2): 58-64.

10.Sumi T, Nagayama D, Suzuki K, Koshino Y, Ikeda T, Watanabe H, Yamada Y, Chiba H. Invasive Mucinous Adenocarcinoma Diagnosed Using Transbronchial Cryobiopsy. Respir Endosc. 2023;1(2):119-122.

11.Sumi T, Terai K, Suzuki K, Koshino Y, Ikeda T, Watanabe H, Yamada Y, Chiba H. Minocycline-induced Acute Fibrinous and Organizing Pneumonia. Am J Respir Crit Care Med. 2023;208(12):e47-e48.

12.角俊行，十良澤太門，鈴木敬仁，越野友太，池田拓海，渡辺裕樹，山田裕一，千葉弘文．ニボルマブ＋イピリムマブ＋プラチナ併用療法施行中，胸膜癒着術後にサイトカイン放出症候群をきたした肺腺癌の一例．肺癌．2023; 63: 971–976./p>

▼2024年

1.Sumi T, Yamada Y, Koshino Y, Watanabe H, Nagayama D, Michimata H, Suzuki K, Ikeda T, Terai K, Osuda K, Tanaka Y, Chiba H. Transbronchial cryobiopsy for small peripheral pulmonary lesions using endobronchial ultrasonography and an ultrathin bronchoscope. Respir Investig. 2024;62:77–84.

2.宮平由佳子，角俊行，鈴木敬仁，越野友太，池田拓海，渡辺裕樹，山田裕一，千葉弘文．肺血栓塞栓症を契機に診断されたROS1融合遺伝子陽性肺腺癌の一例．肺癌．2024;64:28–33.

3.Sumi T, Sakakibara-Konishi J, Suzuki K, Chiba H. Drop finger caused by lung cancer metastasis. Respirol Case Rep. 2024;12(1):e01280.

4.Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer Sci. Published online January 29, 2024. doi:10.1111/cas.16094

5.Sumi T, Suzuki K, Koshino Y, Ikeda T, Yamada Y, Chiba H. Sputum colour: An indicator of Legionella pneumophilapneumonia. Respirol Case Rep. 2024 Feb 28;12(3):e01312.

6.Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024 Apr 1;10(4):439-447.

7.Shijubou N, Sumi T, Kubo T, Sasaki K, Tsukahara T, Kanaseki T, Murata K, Keira Y, Terai K, Ikeda T, Yamada Y, Chiba H, Hirohashi Y, Torigoe T. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2024;150(3):125

8.Sumi T, Suzuki K, Koshino Y, Ikeda T, Yamada Y, Chiba H. Successful Treatment of Mucus Plug Due to Allergic Bronchopulmonary Aspergillosis Using Dupilumab. Cureus. 2024 Mar 10;16(3):e55884

9.Sumi T, Watanabe Y, Arioka K, Chiba H. Eyelid Edema in Eosinophilic Granulomatosis with Polyangiitis. Intern Med. 2024 Jun 13. doi: 10.2169/internalmedicine.3619-24.

10.Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Suzuki K, Ikeda T, Michimata H, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H. Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer. Thorac Cancer. 2024 Jul;15(20):1572-1581.

11.Sumi T, Suzuki K, Arioka K, Chiba H. Methotrexate-associated lymphoproliferative disorder of the heart. Jpn J Clin Oncol. 2024 Volume 54, Issue 11, November 2024, Pages 1226–1227. doi: 10.1093/jjco/hyae091.

12.Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer Med. 2024 Jul;13(14):e70036.

13.越野友太，角俊行，鈴木敬仁，池田拓海，山田裕一，慶谷友基，青栁美穂，上原浩文，有岡琴美，千葉弘文．肺葉切除後にニボルマブと化学療法によるネオアジュバント療法の免疫関連有害事象としての胸膜炎を発症した一例．肺癌．2024;64:315–320.

14.Sumi T, Suzuki K, Arioka K, Chiba H. Methotrexate-associated lymphoproliferative disorder of the heart. Jpn J Clin Oncol. 2024 Jul 18:hyae091. doi: 10.1093/jjco/hyae091.

15.Sumi T, Ishigooka T, Matsuura K, Ikeda T, Koshino Y, Suzuki K, Arioka K, Yamada Y, Chiba H. Transesophageal ultrasound-guided bronchoscopic Acquire TBNB versus Vizishot2 TBNA needles for neoplastic lesions: A retrospective study. Respir Investig. 2024 Sep 4;62(6):1021-1026. doi: 10.1016/j.resinv.2024.08.016.

16.Sumi T, Ikeda T, Arioka K, Sakuma Y, Yamaguchi M, Ishigooka T, Matsuura K, Yamada Y, Chiba H. Esophagomediastinal fistula during durvalumab plus tremelimumab with chemotherapy in angiotensin-converting enzyme 2-positive non-small cell lung cancer: a case report. Transl Lung Cancer Res 2024;13(10):2847-2852.

17.Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H. Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001. Jpn J Clin Oncol. 2024 Dec 4:hyae168. doi: 10.1093/jjco/hyae168.

▼2025年

1. Sumi T, Nagano Y, Yokoo K, Ishikawa T, Nishikiori H, Honjo O, Kudo S, Yamazoe M, Kondoh S, Shioya M, Otsuka M, Hashimoto M, Yabe H, Tanaka Y, Sudo Y, Yanagi M, Takahashi M, Chiba H. Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study. Cancer Immunol Immunother. 2025 Jan 3;74(2):39. doi: 10.1007/s00262-024-03890-4. PMID: 39751674.

2. Sumi T, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Chiba H. Cytokine release syndrome induced by dabrafenib and trametinib therapy in BRAF V600E-mutant non-small cell lung cancer. Jpn J Clin Oncol. 2025 Jan 17:hyaf004. doi: 10.1093/jjco/hyaf004. Epub ahead of print. PMID: 39821273.

3. Sumi T, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Shijubou N, Kubo T, Chiba H. Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report. Lung Cancer. 2025 Feb 3;201:108420. doi: 10.1016/j.lungcan.2025.108420. Epub ahead of print. PMID: 39919549.

4. Moniwa K, Tokita S, Sumi T, Saijo H, Sugita S, Arioka K, Hirohashi Y, Chiba H, Kanaseki T, Torigoe T. Loss of Tapasin in Tumors Potentiates T-Cell Recognition and Anti-Tumor Effects of Immune Checkpoint Blockade. Cancer Sci. 2025 Feb 24. doi: 10.1111/cas.70027. Epub ahead of print. PMID: 39989216.

5. 松浦 啓吾, 角 俊行, 藤森 賢人, 鎌田 弘毅, 小林 智史, 大塚 満雄, 石郷岡 大樹, 池田 拓海, 山田 裕一, 千葉 弘文, ニボルマブ＋イピリムマブ療法中にサイトカイン放出症候群を繰り返し，再燃の契機として細菌感染症が疑われた1例, 肺癌, 2025, 65 巻, 1 号, p. 54-59

6. Sumi T, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Chiba H. Transbronchial Lung Cryobiopsy as a Diagnostic Tool for Gastric Cancer-induced Pulmonary Tumor Thrombotic Microangiopathy. Respir Endosc. 2025;3(1):18-21.

7. Sumi T, Uehara H, Arioka K, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Chiba H. Visceral Pleural Perforation from within a Tumor during Ultrathin Bronchoscopy. Respir Endosc. 2025;3(1):27-30.

8. Nagano Y, Takahashi M, Sumi T, Yokoo K, Ishikawa T, Honjo O, Kudo S, Kondo S, Tanaka Y, Shioya M, Hashimoto M, Otsuka M, Sudo Y, Yanagi M, Yabe H, Nishikiori H, Yamazoe M, Asai Y, Fukataki Y, Hinotsu S, Chiba H. Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study. Jpn J Clin Oncol. 2025 May 7:hyaf073. doi: 10.1093/jjco/hyaf073. Epub ahead of print. PMID: 40333938.

9. Sumi T, Ishigooka T, Matsuura K, Ikeda T, Koshino Y, Suzuki K, Yamada Y, Chiba H. Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study. Respir Investig. 2025 May 7;63(4):592-599. doi: 10.1016/j.resinv.2025.04.022. Epub ahead of print. PMID: 40339469.

10.Sumi T, Kanamaru K, Tsuji S, Kagawa M, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Chiba H. Prophylactic Interventions to Prevent Severe Skin Toxicities in Patients With Non-Small Cell Lung Cancer Treated With Nivolumab + Ipilimumab With or Without Chemotherapy. JCO Oncol Pract. 2025 Jun 30:OP2500100. doi: 10.1200/OP-25-00100. Epub ahead of print. PMID: 40587818.

11.Shiono A, Imai H, Kaira K, Abe T, Sato Y, Yamamoto K, Watanabe H, Tsuchiya-Kawano Y, Tamiya A, Osaki T, Yanagitani N, Tanzawa S, Sumi T, Yoshimine K, Matsui Y, Endo S, Shibata K, Takemoto S, Miura Y, Nagai Y, Nakagawa J, Tsuda T, Kagamu H. Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study. Thorac Cancer. 2025 Jul;16(13):e70118. doi: 10.1111/1759-7714.70118. PMID: 40583736.

12.Ishii H, Azuma K, Kiyomi F, Yoshimine K, Uchida K, Tobino K, Yamada T, Iwasa T, Kanemura H, Sumi T, Iwama E, Mori M, Takenaka M, Takeyasu Y, Kurata T, Misono S, Tanaka K, Okamoto I. Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study). Cancer Treat Res Commun. 2025 Sep 27;45:101008. doi: 10.1016/j.ctarc.2025.101008. Epub ahead of print. PMID: 41037966.

13.Shijubou N, Sumi T, Ishigooka T, Naraoka T, Takeda K, Yamada Y, Chiba H. Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer. Lung Cancer. 2025 Aug 26;207:108730. doi: 10.1016/j.lungcan.2025.108730. Epub ahead of print. PMID: 40882294.

14.Sumi T, Takeda K. An Unexpected Cause of Tongue Deviation. Intern Med. 2025 Nov 13. doi: 10.2169/internalmedicine.6437-25. Epub ahead of print. PMID: 41224276.

15.竹村 壮大郎, 角 俊行, 池田 拓海, 松浦 啓吾, 石郷岡 大樹, 山田 裕一, 千葉 弘文. 副腎転移からの出血により急性腹症を呈し，経カテーテル動脈塞栓術により治療した進行肺腺癌の1例. 肺癌．2025;65:1035-1040

▼2026年

1. Saijo H, Hirohashi Y, Sumi T, Shijubo N, Saito A, Honjo O, Saikai T, Takabatake H, Fujita A, Honda Y, Koba H, Chiba H, Torigoe T. Tumor Stroma Infiltrating T Cells Predict the Efficacy of Anti-CTLA-4 Antibody in NSCLC. Anticancer Res. 2026 Jan;46(1):301-308. doi: 10.21873/anticanres.17944. PMID: 41469097.